Renaissance Technologies (RenTech)'s BCYC Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 979,300 shares of Bicycle Therapeutics plc (BCYC) worth $4.54 M, representing 0.01% of the portfolio. First purchased in 2020-Q1, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in BCYC, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 412,700 shares. Largest reduction occurred in Q3 2022, reducing 153,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Bicycle Therapeutics plc (BCYC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bicycle Therapeutics plc (BCYC) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +412,700 | Add 72.84% | 979,300 | $4.64 |
| Q4 2025 | +47,900 | Add 9.23% | 566,600 | $7.08 |
| Q3 2025 | +200,300 | Add 62.91% | 518,700 | $7.74 |
| Q2 2025 | +16,900 | Add 5.61% | 318,400 | $6.95 |
| Q1 2025 | +32,000 | Add 11.87% | 301,500 | $8.49 |
| Q4 2024 | -3,100 | Reduce 1.14% | 269,500 | $14.00 |
| Q3 2024 | -54,200 | Reduce 16.59% | 272,600 | $22.63 |
| Q2 2024 | +161,100 | Add 97.22% | 326,800 | $20.24 |
| Q1 2024 | +60,200 | Add 57.06% | 165,700 | $24.90 |
| Q4 2023 | +23,500 | Add 28.66% | 105,500 | $18.08 |
| Q3 2023 | +11,100 | Add 15.66% | 82,000 | $20.09 |
| Q2 2023 | +9,000 | Add 14.54% | 70,900 | $0.03 |
| Q1 2023 | +61,900 | New Buy | 61,900 | $0.02 |
| Q3 2022 | -153,200 | Sold Out | 0 | $0.00 |
| Q2 2022 | +88,801 | Add 137.89% | 153,200 | $16.78 |
| Q1 2022 | -8,780 | Reduce 12.00% | 64,399 | $43.88 |
| Q4 2021 | +73,179 | New Buy | 73,179 | $60.86 |
| Q3 2021 | -14,600 | Sold Out | 0 | $0.00 |
| Q2 2021 | -12,200 | Reduce 45.52% | 14,600 | $30.34 |
| Q1 2021 | -54,400 | Reduce 67.00% | 26,800 | $29.89 |
| Q4 2020 | +21,700 | Add 36.47% | 81,200 | $17.96 |
| Q3 2020 | -15,200 | Reduce 20.35% | 59,500 | $19.04 |
| Q2 2020 | +55,900 | Add 297.34% | 74,700 | $15.74 |
| Q1 2020 | +18,800 | New Buy | 18,800 | $13.67 |
Renaissance Technologies (RenTech)'s Bicycle Therapeutics plc Investment FAQs
Renaissance Technologies (RenTech) first purchased Bicycle Therapeutics plc (BCYC) in Q1 2020, acquiring 18,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Bicycle Therapeutics plc (BCYC) for 24 quarters since Q1 2020.
Renaissance Technologies (RenTech)'s largest addition to Bicycle Therapeutics plc (BCYC) was in Q1 2026, adding 979,300 shares worth $4.54 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 979,300 shares of Bicycle Therapeutics plc (BCYC), valued at approximately $4.54 M.
As of the Q1 2026 filing, Bicycle Therapeutics plc (BCYC) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Bicycle Therapeutics plc (BCYC) was 979,300 shares, as reported at the end of Q1 2026.